A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer

A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01851746

Enrollment

200

Registered

2013-05-10

Start date

2013-03-31

Completion date

2015-02-28

Last updated

2013-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Ovarian Cancer

Keywords

recurrent ovarian cancer, lobaplatin, docetaxel, carboplatin

Brief summary

The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. age between 18 and 70 years old 2. singed the information consent form 3. Expected survival time \>3 months 4. Recurrence for at least 6 months after receiving initial platinum-based chemotherapy and without cytoreductive surgery indications.

Exclusion criteria

1. Recurrence within 6 months after receiving initial platinum-based chemotherapy 2. without radiographic evidence for tumor recurrence 3. receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy

Design outcomes

Primary

Measure	Time frame	Description
Evidence of the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.	from pre-chemotherapy to 4-6 weeks post-chemotherapy	Blood routine, urine routine, hepatic and kidney function, electrolyte, ECG, CT,MRI

Countries

China

Outcome results